402 related articles for article (PubMed ID: 20166769)
1. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
Leporini C; Patanè M; Saullo F; Rende P; Gallelli L; Di Paola ED; Toscano R; Lucia M; Rossi M; De Sarro G; Russo E
BioDrugs; 2014 Dec; 28(6):499-511. PubMed ID: 25209722
[TBL] [Abstract][Full Text] [Related]
5. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
7. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of trabectedin in treating ovarian cancer.
Teplinsky E; Herzog TJ
Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
Sehouli J; Alfaro V; González-Martín A
Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin: Supportive care strategies and safety profile.
Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J
Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812
[TBL] [Abstract][Full Text] [Related]
11. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Lisyanskaya AS; Makhson AN; Rolski J; Gorbounova VA; Ghatage P; Bidzinski M; Shen K; Ngan HY; Vergote IB; Nam JH; Park YC; Lebedinsky CA; Poveda AM
J Clin Oncol; 2010 Jul; 28(19):3107-14. PubMed ID: 20516432
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.
Del Campo JM; Muñoz-Couselo E; Diaz de Corcuera I; Oaknin A
Expert Rev Anticancer Ther; 2010 Jun; 10(6):795-805. PubMed ID: 20553205
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
Monk BJ; Dalton H; Benjamin I; Tanović A
Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
López-Guerrero JA; Romero I; Poveda A
Chin J Cancer; 2015 Jan; 34(1):41-9. PubMed ID: 25556617
[TBL] [Abstract][Full Text] [Related]
16. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Jones RL; Herzog TJ; Patel SR; von Mehren M; Schuetze SM; Van Tine BA; Coleman RL; Knoblauch R; Triantos S; Hu P; Shalaby W; McGowan T; Monk BJ; Demetri GD
Cancer Med; 2021 Jun; 10(11):3565-3574. PubMed ID: 33960681
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
Schöffski P; Dumez H; Wolter P; Stefan C; Wozniak A; Jimeno J; Van Oosterom AT
Expert Opin Pharmacother; 2008 Jun; 9(9):1609-18. PubMed ID: 18518789
[TBL] [Abstract][Full Text] [Related]
19. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin for the therapy of ovarian cancer.
Evangelisti G; Barra F; D'Alessandro G; Tantari M; Stigliani S; Della Corte L; Bifulco G; Ferrero S
Drugs Today (Barc); 2020 Oct; 56(10):669-688. PubMed ID: 33185631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
